Menu

The University of Michigan treats cancer patients, including those with mesothelioma, at the Rogel Cancer Center. Mesothelioma is treated through their Thoracic Oncology Program, which is also where they conduct research in an effort to find more effective treatments.

Within this program is a team of thoracic surgeons, medical oncologists, radiation oncologists, pulmonologists, gastroenterologists, radiologists, pathologists and nurses. The multidisciplinary team works to provide each patient with a personalized treatment plan, consisting commonly of surgery, radiation and chemotherapy.

Rogel Cancer Center also practices the use of heated intraperitoneal chemotherapy (HIPEC), a heated chemotherapy wash, in the treatment of peritoneal mesothelioma. For patients interested in experimental treatments for mesothelioma, clinical trials are offered through the University of Michigan Cancer Center for those who are eligible.

If patients choose to receive care from UM Rogel Cancer Center, they can utilize a variety of resources. There is a patient assistance center that helps families with everything from exploring financial assistance options to lodging and parking. They also offer complementary therapies to help patients on their treatment journey, including art therapy and guided imagery therapy.

Specializations:

  • HIPEC
  • Lung cancer
  • Mesothelioma
  • Peritoneal mesothelioma
  • Pleural mesothelioma

Accreditations:

  • Blue Distinction Center for Complex and Rare Cancers designation
  • Commission on Cancer of the American College of Surgeons accreditation
  • Joint Commission accreditation
  • Michigan Cancer Consortium member
  • National Cancer Institute Comprehensive Cancer Center designation
  • National Comprehensive Cancer Network member
  • Oncology Care Model designation
  • The Quality Oncology Practice Initiative recognition

Mesothelioma Clinical Trials at University of Michigan

The following clinical trials are in progress or actively recruiting participants at University of Michigan:

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors


Conditions: Carcinoma, Carcinoma, Squamous Cell, Adenocarcinoma, Neoplasms, Germ Cell and Embryonal, Mesothelioma, Breast Neoplasms, Nasopharyngeal Carcinoma, Cholangiocarcinoma, Carcinoma, Basal Cell, Gastrointestinal Stromal Tumors, Carcinoid Tumor, Carcinoma, Transitional Cell, Carcinoma, Adenoid Cystic, Teratoma, Adenocarcinoma of Lung, Carcinoma, Neuroendocrine, Seminoma, Pheochromocytoma, Choriocarcinoma, Cystadenocarcinoma, Cystadenocarcinoma, Serous, Carcinoma, Endometrioid, Chordoma, Paraganglioma, Hemangiosarcoma, Fibromatosis, Aggressive, Trophoblastic Neoplasms, Adenocarcinoma, Mucinous, Gestational Trophoblastic Disease, Adenocarcinoma, Clear Cell, Nerve Sheath Neoplasms, Neurofibrosarcoma, Cystadenocarcinoma, Mucinous, Fibroma, Thyroid Neoplasms, Pseudomyxoma Peritonei, Sex Cord-Gonadal Stromal Tumors, Adrenocortical Carcinoma, Carcinoma, Islet Cell, Vulvar Neoplasms, Paget Disease, Extramammary, Adenocarcinoma, Papillary, Carcinoma, Acinar Cell, Adenocarcinoma, Bronchiolo-Alveolar, Mixed Tumor, Mullerian, Carcinoma, Giant Cell, Neoplasms, Unknown Primary, Neoplasms

Last Updated: September 27, 2019

Status: Recruiting

Photo of University of Michigan

Get Help Contacting University of Michigan


    Privacy policy: All information is secure and will never be released

    TRUSTe

    Free

    Mesothelioma Treatment Guide

    Please fill in the form to request our FREE Mesothelioma Treatment Guide.
    It will be sent to you within 24 hours.

    Free Mesothelioma Treatment Guide



      Privacy policy: All information is secure and will never be released

      TRUSTe